Health Care [ 11/12 ] | Biotechnology [ 55/73 ]
NASDAQ | Common Stock
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases.
The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis.
It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy.
Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 5, 25 | -0.92 Decreased by -17.95% | -0.75 Decreased by -23.18% |
| Feb 25, 25 | -0.82 Decreased by -18.84% | -0.96 Increased by +14.15% |
| Nov 7, 24 | -0.95 Decreased by -35.71% | -0.97 Increased by +2.06% |
| Aug 7, 24 | -0.92 Decreased by -31.43% | -0.85 Decreased by -8.24% |
| May 6, 24 | -0.78 Decreased by -16.42% | -0.77 Decreased by -1.30% |
| Feb 27, 24 | -0.69 Increased by +4.17% | -0.81 Increased by +14.81% |
| Nov 9, 23 | -0.70 Decreased by -7.69% | -0.77 Increased by +9.09% |
| Aug 9, 23 | -0.70 Increased by +14.63% | -0.71 Increased by +1.41% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -56.17 M Decreased by -19.62% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -49.73 M Decreased by -20.98% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -57.76 M Decreased by -39.23% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -55.85 M Decreased by -35.59% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -46.95 M Decreased by -66.84% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 4.84 M Increased by +146.31% | -41.11 M Decreased by -18.79% | Decreased by -849.36% Increased by +51.77% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -41.49 M Decreased by -48.43% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 248.00 K Decreased by -95.03% | -41.19 M Decreased by -39.42% | Decreased by -16.61 K% Decreased by -2.70 K% |